Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFH375 vs investigator-choice chemotherapy in previously treated metastatic pancreatic cancer with KRAS G12D mutation
CTR20254503Phase 3Active
- Sponsor
- GenFleet Therapeutics
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of GFH375 in pancreatic cancer (PDAC), sponsored by GenFleet Therapeutics. Started Dec 2025; status: active.
02
Drugs
GFH375
03
Conditions
pancreatic cancer (PDAC)
Beyond the preview
Go deeper on CTR20254503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254503.